Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval ...

As biologic options have expanded for the treatment of chronic spontaneous urticaria (CSU), the question of which one works best has gained importance.

'Common Sense' Department: When the new NYC mayor-elect is actually doing things that sound like their headlines from 'The Onion,' you know we’re living in strange times... Senate to vote Friday on ...

Welcome Back to the Daily Aviation as we explore the rapid rise of drones in modern warfare and the countermeasures developed to stop them from the cheapest to more expensive solutions. Voice, text ...

The tariffs at the heart of this week's Supreme Court case are raising tens of billions of dollars for the federal government. They're also costing consumers, frustrating businesses and hurting the ...

As open enrollment begins for millions of Americans, young adults who have aged out of their parents' health insurance plans are confronting what advocates call a "health insurance cliff" — a sharp ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.